ZVRA
Zevra Therapeutics, Inc.$11.64-0.03 (-0.21%)Prev Close$11.67·MCap$686.3M·P/E5.42·Vol324.8K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
22
$4.17M
◆
Net Activity
Net Seller
$4.17M
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Zevra Therapeutics, Inc. (ZVRA) has been exclusively selling, with 0 insider purchases totaling $0.00 and 22 insider sales totaling $4.17M. The most recent insider transaction was by Thompson Rahsaan (officer: Chief Legal & Compliance), who sold $474.8K worth of shares on Aug 17, 2026. Zevra Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $686.3M.
ZVRA Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Thompson Rahsaan | officer: Chief Legal & Compliance | Sell | 42,666 | $11.13 | $474.8K | 37,569-53% |
| Aug 12, 2026 | Watton Corey Michael | director | Sell | 12,300 | $11.25 | $138.4K | 1,800-87% |
| Jun 23, 2026 | Thompson Rahsaan | officer: Chief Legal & Compliance | Sell | 34,557 | $12.68 | $438.3K | 80,235-30% |
| May 13, 2026 | Thompson Rahsaan | officer: Chief Legal & Compliance | Sell | 1,794 | $11.30 | $20.3K | 48,125 |
| Feb 10, 2026 | McFarlane Neil F. | director, officer: President and CEO | Sell | 14,625 | $8.56 | $125.2K | 387,225 |
| Feb 7, 2026 | McFarlane Neil F. | President and CEO | Sell | 14,625 | $8.56 | $125.2K | 0 |
| Feb 4, 2026 | Sangiovanni Timothy J. | officer: SVP, Finance & Corp Controller | Sell | 3,000 | $9.18 | $27.5K | 29,590 |
| Feb 4, 2026 | Schafer Joshua | officer: CCO | Sell | 10,500 | $9.19 | $96.5K | 62,278 |
| Feb 3, 2026 | Sangiovanni Timothy J. | SVP, Finance & Corp Controller | Sell | 3,000 | $9.18 | $27.5K | 0 |
| Feb 3, 2026 | Schafer Joshua | CCO | Sell | 10,500 | $9.19 | $96.5K | 0 |
| Feb 2, 2026 | McFarlane Neil F. | director, officer: President and CEO | Sell | 91,000 | $9.38 | $853.4K | 364,350 |
| Feb 2, 2026 | Quartel Adrian W | officer: Chief Medical Officer | Sell | 4,533 | $8.83 | $40.0K | 9,723-32% |
| Feb 2, 2026 | Sangiovanni Timothy J. | officer: SVP, Finance & Corp Controller | Sell | 1,750 | $8.82 | $15.4K | 20,924 |
| Feb 2, 2026 | Schafer Joshua | officer: CCO | Sell | 3,375 | $8.83 | $29.8K | 37,444 |
| Feb 2, 2026 | Thompson Rahsaan | officer, other: Chief Legal & Compliance | Sell | 4,080 | $8.83 | $36.0K | 49,919 |
| Jan 30, 2026 | Sangiovanni Timothy J. | SVP, Finance & Corp Controller | Sell | 1,750 | $8.82 | $15.4K | 0 |
| Jan 29, 2026 | McFarlane Neil F. | President and CEO | Sell | 91,000 | $9.38 | $853.4K | 0 |
| Jan 29, 2026 | Quartel Adrian W | Chief Medical Officer | Sell | 4,533 | $8.83 | $40.0K | 0 |
| Jan 29, 2026 | Schafer Joshua | CCO | Sell | 3,375 | $8.83 | $29.8K | 0 |
| Jan 29, 2026 | Thompson Rahsaan | Chief Legal & Compliance | Sell | 4,080 | $8.83 | $36.0K | 0 |
| Dec 31, 2025 | Clifton R. LaDuane | Insider | Sell | 48,513 | $8.96 | $434.7K | 0 |
| Oct 10, 2025 | McFarlane Neil F. | President and CEO | Sell | 19,500 | $10.82 | $210.9K | 0 |
| Sep 12, 2025 | FAVORITO TAMARA A | Director | Buy | 3,175 | $7.79 | $24.7K | 0 |
| Sep 12, 2025 | Shih Alvin | Director | Buy | 20,000 | $7.89 | $157.8K | 0 |
| Aug 19, 2025 | Bode John B | Director | Buy | 5,000 | $9.17 | $45.8K | 0 |
| Jun 26, 2025 | Thompson Rahsaan | Chief Legal & Compliance | Sell | 24,000 | $9.21 | $221.0K | 0 |
| Mar 28, 2025 | Watton Corey Michael | Director | Buy | 300 | $7.84 | $2.4K | 0 |
| Mar 19, 2025 | Bode John B | Director | Buy | 10,000 | $7.96 | $79.6K | 0 |
| Feb 14, 2025 | Clifton R. LaDuane | CFO & Treasurer | Sell | 11,000 | $7.86 | $86.5K | 51,361 |
| Feb 14, 2025 | McFarlane Neil F. | President and CEO | Sell | 91,817 | $7.92 | $727.4K | 222,060-29% |
| Feb 14, 2025 | Sangiovanni Timothy J. | SVP, Finance & Corp Controller | Sell | 3,000 | $7.86 | $23.6K | 16,341 |
| Feb 14, 2025 | Schafer Joshua | CCO & EVP, Bus. Development | Sell | 10,500 | $7.86 | $82.5K | 29,486-26% |
| Oct 16, 2024 | Watton Corey Michael | Director | Buy | 500 | $7.92 | $4.0K | 1,500+50% |
| Jul 17, 2024 | Clifton R. LaDuane | CFO & Treasurer | Buy | 2,000 | $6.77 | $13.5K | 18,469 |
| Jul 16, 2024 | Anderson Thomas | Director | Buy | 10,000 | $6.81 | $68.1K | 20,000+100% |
| Jul 15, 2024 | Bode John B | Director | Buy | 10,000 | $5.87 | $58.7K | 30,000+50% |
| Sep 6, 2023 | Anderson Thomas | Director | Buy | 10,000 | $4.88 | $48.8K | 10,000 |
| Sep 6, 2023 | Bode John B | Director | Buy | 10,000 | $5.13 | $51.3K | 20,000+100% |
| Sep 6, 2023 | Clifton R. LaDuane | CFO, Secretary & Treasurer | Buy | 1,000 | $4.96 | $5.0K | 15,309 |
| Sep 6, 2023 | Schafer Joshua | CCO & EVP, Bus. Development | Buy | 500 | $5.13 | $2.6K | 3,500 |
| Jun 30, 2023 | Schafer Joshua | CCO & EVP, Bus. Development | Buy | 1,000 | $5.42 | $5.4K | 3,000+50% |
| Jun 26, 2023 | Watton Corey Michael | Director | Buy | 275 | $5.95 | $1.6K | 1,000+38% |
| Jun 13, 2023 | Watton Corey Michael | Director | Buy | 325 | $5.52 | $1.8K | 725+81% |
| May 31, 2023 | Watton Corey Michael | Director | Buy | 400 | $5.11 | $2.0K | 400 |
| May 19, 2023 | Bode John B | Director | Buy | 10,000 | $5.04 | $50.4K | 10,000 |
| May 18, 2023 | Clifton R. LaDuane | CFO, Secretary & Treasurer | Buy | 2,740 | $4.95 | $13.6K | 13,742 |
| Mar 21, 2023 | SEYMOUR TAMARA A | Director | Buy | 519 | $4.82 | $2.5K | 719+260% |
| Mar 15, 2023 | Schafer Joshua | CCO & EVP, Bus. Development | Buy | 2,000 | $4.61 | $9.2K | 2,000 |
| Mar 13, 2023 | Clifton R. LaDuane | CFO, Secretary & Treasurer | Buy | 1,725 | $4.15 | $7.2K | 11,002 |
| Mar 13, 2023 | Pascoe Richard W | Chief Executive Officer | Buy | 10,000 | $4.20 | $42.0K | 29,973+50% |
Showing 1–50 of 74
1 / 2
ZVRA Insider Buying Activity
The following table shows recent insider purchases of Zevra Therapeutics, Inc. (ZVRA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 12, 2025 | FAVORITO TAMARA A | Director | Buy | 3,175 | $7.79 | $24.7K | 0 |
| Sep 12, 2025 | Shih Alvin | Director | Buy | 20,000 | $7.89 | $157.8K | 0 |
| Aug 19, 2025 | Bode John B | Director | Buy | 5,000 | $9.17 | $45.8K | 0 |
| Mar 28, 2025 | Watton Corey Michael | Director | Buy | 300 | $7.84 | $2.4K | 0 |
| Mar 19, 2025 | Bode John B | Director | Buy | 10,000 | $7.96 | $79.6K | 0 |
| Oct 16, 2024 | Watton Corey Michael | Director | Buy | 500 | $7.92 | $4.0K | 1,500+50% |
| Jul 17, 2024 | Clifton R. LaDuane | CFO & Treasurer | Buy | 2,000 | $6.77 | $13.5K | 18,469 |
| Jul 16, 2024 | Anderson Thomas | Director | Buy | 10,000 | $6.81 | $68.1K | 20,000+100% |
| Jul 15, 2024 | Bode John B | Director | Buy | 10,000 | $5.87 | $58.7K | 30,000+50% |
| Sep 6, 2023 | Anderson Thomas | Director | Buy | 10,000 | $4.88 | $48.8K | 10,000 |
| Sep 6, 2023 | Bode John B | Director | Buy | 10,000 | $5.13 | $51.3K | 20,000+100% |
| Sep 6, 2023 | Clifton R. LaDuane | CFO, Secretary & Treasurer | Buy | 1,000 | $4.96 | $5.0K | 15,309 |
| Sep 6, 2023 | Schafer Joshua | CCO & EVP, Bus. Development | Buy | 500 | $5.13 | $2.6K | 3,500 |
| Jun 30, 2023 | Schafer Joshua | CCO & EVP, Bus. Development | Buy | 1,000 | $5.42 | $5.4K | 3,000+50% |
| Jun 26, 2023 | Watton Corey Michael | Director | Buy | 275 | $5.95 | $1.6K | 1,000+38% |
| Jun 13, 2023 | Watton Corey Michael | Director | Buy | 325 | $5.52 | $1.8K | 725+81% |
| May 31, 2023 | Watton Corey Michael | Director | Buy | 400 | $5.11 | $2.0K | 400 |
| May 19, 2023 | Bode John B | Director | Buy | 10,000 | $5.04 | $50.4K | 10,000 |
| May 18, 2023 | Clifton R. LaDuane | CFO, Secretary & Treasurer | Buy | 2,740 | $4.95 | $13.6K | 13,742 |
| Mar 21, 2023 | SEYMOUR TAMARA A | Director | Buy | 519 | $4.82 | $2.5K | 719+260% |
| Mar 15, 2023 | Schafer Joshua | CCO & EVP, Bus. Development | Buy | 2,000 | $4.61 | $9.2K | 2,000 |
| Mar 13, 2023 | Clifton R. LaDuane | CFO, Secretary & Treasurer | Buy | 1,725 | $4.15 | $7.2K | 11,002 |
| Mar 13, 2023 | Pascoe Richard W | Chief Executive Officer | Buy | 10,000 | $4.20 | $42.0K | 29,973+50% |
ZVRA Insider Selling Activity
The following table shows recent insider sales of Zevra Therapeutics, Inc. (ZVRA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Thompson Rahsaan | officer: Chief Legal & Compliance | Sell | 42,666 | $11.13 | $474.8K | 37,569-53% |
| Aug 12, 2026 | Watton Corey Michael | director | Sell | 12,300 | $11.25 | $138.4K | 1,800-87% |
| Jun 23, 2026 | Thompson Rahsaan | officer: Chief Legal & Compliance | Sell | 34,557 | $12.68 | $438.3K | 80,235-30% |
| May 13, 2026 | Thompson Rahsaan | officer: Chief Legal & Compliance | Sell | 1,794 | $11.30 | $20.3K | 48,125 |
| Feb 10, 2026 | McFarlane Neil F. | director, officer: President and CEO | Sell | 14,625 | $8.56 | $125.2K | 387,225 |
| Feb 7, 2026 | McFarlane Neil F. | President and CEO | Sell | 14,625 | $8.56 | $125.2K | 0 |
| Feb 4, 2026 | Sangiovanni Timothy J. | officer: SVP, Finance & Corp Controller | Sell | 3,000 | $9.18 | $27.5K | 29,590 |
| Feb 4, 2026 | Schafer Joshua | officer: CCO | Sell | 10,500 | $9.19 | $96.5K | 62,278 |
| Feb 3, 2026 | Sangiovanni Timothy J. | SVP, Finance & Corp Controller | Sell | 3,000 | $9.18 | $27.5K | 0 |
| Feb 3, 2026 | Schafer Joshua | CCO | Sell | 10,500 | $9.19 | $96.5K | 0 |
| Feb 2, 2026 | McFarlane Neil F. | director, officer: President and CEO | Sell | 91,000 | $9.38 | $853.4K | 364,350 |
| Feb 2, 2026 | Quartel Adrian W | officer: Chief Medical Officer | Sell | 4,533 | $8.83 | $40.0K | 9,723-32% |
| Feb 2, 2026 | Sangiovanni Timothy J. | officer: SVP, Finance & Corp Controller | Sell | 1,750 | $8.82 | $15.4K | 20,924 |
| Feb 2, 2026 | Schafer Joshua | officer: CCO | Sell | 3,375 | $8.83 | $29.8K | 37,444 |
| Feb 2, 2026 | Thompson Rahsaan | officer, other: Chief Legal & Compliance | Sell | 4,080 | $8.83 | $36.0K | 49,919 |
| Jan 30, 2026 | Sangiovanni Timothy J. | SVP, Finance & Corp Controller | Sell | 1,750 | $8.82 | $15.4K | 0 |
| Jan 29, 2026 | McFarlane Neil F. | President and CEO | Sell | 91,000 | $9.38 | $853.4K | 0 |
| Jan 29, 2026 | Quartel Adrian W | Chief Medical Officer | Sell | 4,533 | $8.83 | $40.0K | 0 |
| Jan 29, 2026 | Schafer Joshua | CCO | Sell | 3,375 | $8.83 | $29.8K | 0 |
| Jan 29, 2026 | Thompson Rahsaan | Chief Legal & Compliance | Sell | 4,080 | $8.83 | $36.0K | 0 |
| Dec 31, 2025 | Clifton R. LaDuane | Insider | Sell | 48,513 | $8.96 | $434.7K | 0 |
| Oct 10, 2025 | McFarlane Neil F. | President and CEO | Sell | 19,500 | $10.82 | $210.9K | 0 |
| Jun 26, 2025 | Thompson Rahsaan | Chief Legal & Compliance | Sell | 24,000 | $9.21 | $221.0K | 0 |
| Feb 14, 2025 | Clifton R. LaDuane | CFO & Treasurer | Sell | 11,000 | $7.86 | $86.5K | 51,361 |
| Feb 14, 2025 | McFarlane Neil F. | President and CEO | Sell | 91,817 | $7.92 | $727.4K | 222,060-29% |
| Feb 14, 2025 | Sangiovanni Timothy J. | SVP, Finance & Corp Controller | Sell | 3,000 | $7.86 | $23.6K | 16,341 |
| Feb 14, 2025 | Schafer Joshua | CCO & EVP, Bus. Development | Sell | 10,500 | $7.86 | $82.5K | 29,486-26% |
ZVRA Insiders
Sangiovanni Timothy J.
SVP, Finance & Corp Controller
Bought $5.0KSold $109.6K
6 tradesLast: Feb 4, 2026
Similar Stocks to ZVRA
VRTX
Vertex Pharmaceuticals Incorporated
$518.01+1.45%
$131.05B
REGN
Regeneron Pharmaceuticals, Inc.
$807.38+1.09%
$81.33B
MRNA
Moderna, Inc.
$183.20+5.90%
$61.12B
RVMD
Revolution Medicines, Inc.
$192.85-0.01%
$41.87B
INSM
Insmed Incorporated
$121.67+0.57%
$26.01B
INCY
Incyte Corporation
$126.99+1.83%
$25.40B
UTHR
United Therapeutics Corporation
$497.16+0.82%
$21.00B
NBIX
Neurocrine Biosciences, Inc.
$142.39-1.09%
$14.70B